Profectus Biosciences Inc., a clinical-stage vaccine company that creates vaccines to prevent and treat cancer and infectious diseases, recently gave a presentation of pre-clinical data for a multi-component vaccine that is designed to protect people from the Zaire and Sudan strains of Ebola and Marburg viruses.
The results of the study show that a single dose of the vaccine, called VesiculoVax RVSVN4CT1 vector, is the best option in combining safe, effective, multi-component vaccines for the two viruses. The study suggests that just one dose of the vector platform vaccine gives people total protection from Marburg and Ebola viruses.
“We have worked for several years to develop a single vaccine to protect against all the filoviruses,”
Profectus
Chief Scientific Officer
John Eldridge, who presented the data, said. “In addition to the 2014 outbreak of Ebola virus in Zaire in West Africa, outbreaks of both Marburg virus and Ebola virus in Sudan have occurred recently and underscore the need for a vaccine that provides broad protection against all filovirus strains.
“These results demonstrate that the components of the VesiculoVax trivalent Ebola/Marburg vaccine do not interfere with each other and work together to provide the needed breadth of protection. With the continued generous support of the MCS-JVAP, BARDA, and the NIH, we are advancing into a series of clinical trials and anticipate the first human dose of the multi-component vaccine will be administered in mid-2016.”
